367 related articles for article (PubMed ID: 16389295)
1. Preclinical neuropharmacology of naratriptan.
Lambert GA
CNS Drug Rev; 2005; 11(3):289-316. PubMed ID: 16389295
[TBL] [Abstract][Full Text] [Related]
2. Naratriptan.
Massiou H
Curr Med Res Opin; 2001; 17 Suppl 1():s51-3. PubMed ID: 12463278
[TBL] [Abstract][Full Text] [Related]
3. Naratriptan: an alternative for migraine.
Dulli DA
Ann Pharmacother; 1999 Jun; 33(6):704-11. PubMed ID: 10410185
[TBL] [Abstract][Full Text] [Related]
4. Naratriptan has a selective inhibitory effect on trigeminovascular neurones at central 5-HT1A and 5-HT(1B/1D) receptors in the cat: implications for migraine therapy.
Boers PM; Donaldson C; Zagami AS; Lambert GA
Cephalalgia; 2004 Feb; 24(2):99-109. PubMed ID: 14728705
[TBL] [Abstract][Full Text] [Related]
5. The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat.
Hoskin KL; Lambert GA; Donaldson C; Zagami AS
Brain Res; 2004 Feb; 998(1):91-9. PubMed ID: 14725972
[TBL] [Abstract][Full Text] [Related]
6. The role of 5-HT1B and 5-HT1D receptors in the selective inhibitory effect of naratriptan on trigeminovascular neurons.
Donaldson C; Boers PM; Hoskin KL; Zagami AS; Lambert GA
Neuropharmacology; 2002 Mar; 42(3):374-85. PubMed ID: 11897116
[TBL] [Abstract][Full Text] [Related]
7. Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target?
Shields KG; Goadsby PJ
Neurobiol Dis; 2006 Sep; 23(3):491-501. PubMed ID: 16875831
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B/1D)) receptors.
Goadsby PJ; Knight Y
Br J Pharmacol; 1997 Nov; 122(5):918-22. PubMed ID: 9384509
[TBL] [Abstract][Full Text] [Related]
9. Modulation of neuronal activity in the nucleus raphé magnus by the 5-HT(1)-receptor agonist naratriptan in rat.
Ellrich J; Messlinger K; Chiang CY; Hu JW
Pain; 2001 Feb; 90(3):227-231. PubMed ID: 11207394
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiology of migraine--new insights.
Hargreaves RJ; Shepheard SL
Can J Neurol Sci; 1999 Nov; 26 Suppl 3():S12-9. PubMed ID: 10563228
[TBL] [Abstract][Full Text] [Related]
11. Is selective 5-HT
Rubio-Beltrán E; Labastida-Ramírez A; Villalón CM; MaassenVanDenBrink A
Pharmacol Ther; 2018 Jun; 186():88-97. PubMed ID: 29352859
[TBL] [Abstract][Full Text] [Related]
12. Lasmiditan mechanism of action - review of a selective 5-HT
Clemow DB; Johnson KW; Hochstetler HM; Ossipov MH; Hake AM; Blumenfeld AM
J Headache Pain; 2020 Jun; 21(1):71. PubMed ID: 32522164
[TBL] [Abstract][Full Text] [Related]
13. Eletriptan: a review of its use in the acute treatment of migraine.
McCormack PL; Keating GM
Drugs; 2006; 66(8):1129-49. PubMed ID: 16789799
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of the 5-HT1B/1D receptor agonists.
Tepper SJ; Rapoport AM; Sheftell FD
Arch Neurol; 2002 Jul; 59(7):1084-8. PubMed ID: 12117355
[TBL] [Abstract][Full Text] [Related]
15. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine.
Bomhof M; Paz J; Legg N; Allen C; Vandormael K; Patel K
Eur Neurol; 1999; 42(3):173-9. PubMed ID: 10529545
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine.
Martin GR
Cephalalgia; 1997 Oct; 17 Suppl 18():4-14. PubMed ID: 9399012
[TBL] [Abstract][Full Text] [Related]
17. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group.
Göbel H; Winter P; Boswell D; Crisp A; Becker W; Hauge T; Mihout B; Niewold J; Tørring J
Clin Ther; 2000 Aug; 22(8):981-9. PubMed ID: 10972634
[TBL] [Abstract][Full Text] [Related]
18. Activation of 5-HT(1B/1D) receptor in the periaqueductal gray inhibits nociception.
Bartsch T; Knight YE; Goadsby PJ
Ann Neurol; 2004 Sep; 56(3):371-81. PubMed ID: 15349864
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
Mannix LK; Savani N; Landy S; Valade D; Shackelford S; Ames MH; Jones MW
Headache; 2007; 47(7):1037-49. PubMed ID: 17635595
[TBL] [Abstract][Full Text] [Related]
20. Rizatriptan: an update of its use in the management of migraine.
Wellington K; Plosker GL
Drugs; 2002; 62(10):1539-74. PubMed ID: 12093318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
